# CytomX Therapeutics, Inc.: overview

CTMX · Nasdaq · CIK 1501989 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctmx.md) · [Financials](/companies/ctmx/financials.md) · [Filings](/companies/ctmx/filings.md) · [Insiders](/companies/ctmx/insiders.md)

Latest reported revenue: [$1.4m](/filings/0001193125-26-337950.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-337950).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [33.4](/filings/0001193125-25-269477.md) | [38.1 d](/filings/0001193125-26-107146.md) | [50.9](/filings/0001193125-26-211868.md) | [18.7](/filings/0001193125-26-337950.md) | [6.0](/filings/0001193125-25-269477.md) | [0.7 d](/filings/0001193125-26-107146.md) | [10.3](/filings/0001193125-26-211868.md) | [1.4](/filings/0001193125-26-337950.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [12.3%](/filings/0001193125-25-269477.md) | [46.4% d](/filings/0001193125-26-107146.md) | [44.4%](/filings/0001193125-26-211868.md) | [(6.9%)](/filings/0001193125-26-337950.md) | [(264.4%)](/filings/0001193125-25-269477.md) | [(4213.0%) d](/filings/0001193125-26-107146.md) | [(191.8%)](/filings/0001193125-26-211868.md) | [(1677.1%)](/filings/0001193125-26-337950.md) |
| Net margin | % | [17.2%](/filings/0001193125-25-269477.md) | [49.6% d](/filings/0001193125-26-107146.md) | [46.2%](/filings/0001193125-26-337950.md) | [(0.8%)](/filings/0001193125-26-337950.md) | [(238.6%)](/filings/0001193125-25-269477.md) | [(3998.5%) d](/filings/0001193125-26-107146.md) | [(177.9%)](/filings/0001193125-26-337950.md) | [(1457.4%)](/filings/0001193125-26-337950.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(20.7) d](/filings/0001193125-25-269477.md) | [(20.0) d](/filings/0001193125-26-107146.md) | [(21.2)](/filings/0001193125-26-211868.md) | [(15.8) d](/filings/0001193125-26-337950.md) | [(15.7) d](/filings/0001193125-25-269477.md) | [(23.4) d](/filings/0001193125-26-107146.md) | [(25.5)](/filings/0001193125-26-211868.md) | [(18.1) d](/filings/0001193125-26-337950.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [37.3](/filings/0000950170-23-009991.md) | [53.2](/filings/0000950170-24-029191.md) | [101](/filings/0000950170-25-034575.md) | [138](/filings/0001193125-26-107146.md) | [76.2](/filings/0001193125-26-107146.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(311.0%)](/filings/0000950170-23-009991.md) | [(190.6%)](/filings/0000950170-24-029191.md) | [(6.4%)](/filings/0000950170-25-034575.md) | [18.1%](/filings/0001193125-26-107146.md) | [(29.3%)](/filings/0001193125-26-107146.md) |
| Net margin | % | [(310.5%)](/filings/0000950170-23-009991.md) | [(186.8%)](/filings/0000950170-24-029191.md) | [(0.6%)](/filings/0000950170-25-034575.md) | [23.1%](/filings/0001193125-26-107146.md) | [(22.8%)](/filings/0001193125-26-107146.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(121)](/filings/0000950170-23-009991.md) | [(113)](/filings/0000950170-24-029191.md) | [(56.9)](/filings/0000950170-25-034575.md) | [(86.5)](/filings/0001193125-26-107146.md) | [(75.8)](/filings/0001193125-26-107146.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ctmx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $122.7m | 32,714,937 |  | Added +759,300 |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $81.4m | 21,703,093 |  | Added +6,690,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $65.8m | 17,559,822 |  | Added +12,331,542 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $56.6m | 15,082,617 |  | Added +4,879,832 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $44.1m | 11,747,236 |  | Added +6,083,828 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $39.1m | 10,439,185 |  | Added +340,361 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $32.0m | 8,525,457 |  | Reduced −207,661 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $29.3m | 7,811,033 |  | Reduced −64,357 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $19.4m | 5,168,961 |  | Added +1,585,976 |
| [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $18.7m | 4,982,124 |  | Reduced −5,000,000 |

## Recent filings

[All 792 filings](/companies/ctmx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 20:10 ET | [8-K](/filings/0001193125-26-338009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338009 |
| 2026-08-06 | 20:05 ET | [10-Q](/filings/0001193125-26-337950.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337950 |
| 2026-07-27 | 12:05 ET | [8-K](/filings/0001193125-26-316929.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-316929 |
| 2026-06-22 | 20:52 ET | [8-K](/filings/0001193125-26-277631.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277631 |
| 2026-06-03 | 20:15 ET | [8-K](/filings/0001193125-26-255467.md) | 1.01 Entry into a material agreement | 0001193125-26-255467 |
| 2026-05-07 | 20:12 ET | [8-K](/filings/0001193125-26-211920.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211920 |
| 2026-05-07 | 20:06 ET | [10-Q](/filings/0001193125-26-211868.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211868 |
| 2026-04-30 | 20:16 ET | [DEF 14A](/filings/0001140361-26-018237.md) | Proxy statement, period 2026-06-17 | 0001140361-26-018237 |
| 2026-03-19 | 20:05 ET | [8-K](/filings/0001193125-26-115958.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-115958 |
| 2026-03-16 | 11:04 ET | [8-K](/filings/0001193125-26-107152.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-107152 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-107146.md), filed Mar 16, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/008bfa9e-d80d-44de-97a0-6587fbcd79b6)

## About the filer

- CIK: 1501989
- Tickers: CTMX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.